The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Pro‐inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T‐lymphocyte infiltration and affect tumour progression
Abstract
Ewing sarcoma is an aggressive round cell sarcoma with poor patient prognosis, particularly in cases of advanced‐stage disease. Dynamic tumor‐host immune interations within the tumor microenvironment may polarize in situ immune responses and shape tumor development and/or progression. To gain insight into the nature of tumour–host immune interactions within the Ewing sarcoma microenvironment, the presence and spatial distribution of infiltrating CD8+/CD4+ T‐lymphocytes were evaluated in therapy‐naive Ewing sarcoma. Expression profiling of 40 different chemokines and several chemokine receptors was performed in therapy‐naive tumours and cell lines by qPCR, immunohistochemistry, and flow cytometry. Considerable inter‐tumour variation was observed regarding density, type, and distribution of infiltrating T‐lymphocytes. Tumour‐infiltrating T‐cells contained significantly higher percentages of CD8+ T‐lymphocytes as compared to stroma‐infiltrating cells, suggesting preferential migration of this T‐cell type into tumour areas. Gene expression levels of several type 1‐associated, pro‐inflammatory chemokines (CXCR3‐ and CCR5‐ligands CXCL9, CXCL10, and CCL5) correlated positively with infiltrating (CD8+) T‐lymphocyte numbers expressing corresponding chemokine receptors. Survival analyses demonstrated an impact of tumour‐infiltrating, and not stroma‐infiltrating, CD8+ T‐lymphocytes on tumour progression. At protein level, both tumour and stromal cells expressed the IFNγ‐inducible chemokines CXCL9 and CXCL10. CCR5‐ligand CCL5 was exclusively expressed by non‐tumoural stromal/infiltrating cells. Together, our results indicate that an inflammatory immune microenvironment with high expression of type 1‐associated chemokines may be critical for the recruitment of (CD8+) T‐lymphocytes expressing corresponding chemokine receptors. The observed impact of tumour‐infiltrating (CD8+) T‐lymphocytes is consistent with a role for adaptive anti‐tumour immunity in the prevention of Ewing sarcoma progression. Recognition of the merits and exploitation/induction of an inflammatory microenvironment may improve the efficacy of natural immune responses against, and (adoptive) immunotherapeutic approaches for, Ewing sarcoma. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Cited by
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716
“In fact, other chemokine systems, such as CCR2, CCR5, CX3CR1, are associated with T cell migration into tumors (Ahrends et al., 2017; Berghuis et al., 2011; Chew et al., 2012; Fridman et al., 2012; González-Martı́n et al., 2011; Harlin et al., 2009; Liu et al., 2015; Mlecnik et al., 2010).”
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
D’Angelo, S. P., Shoushtari, A. N., Agaram, N. P., Kuk, D., Qin, L.-X., Carvajal, R. D., Dickson, M. A., Gounder, M., Keohan, M. L., Schwartz, G. K., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2014.11.001 · Cited by 301
A proposed role for neutrophil extracellular traps in cancer immunoediting
Berger-Achituv, S., Brinkmann, V., Abed, U. A., Kühn, L. I., Ben-Ezra, J., Elhasid, R., & Zychlinsky, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00048 · Cited by 288
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
Metadata
- Authors
- Berghuis, D., Santos, S. J., Baelde, H. J., Taminiau, A. H., Maarten Egeler, R., Schilham, M. W., Hogendoorn, P. C., & Lankester, A. C.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2010-12-10
- Volume
- 223
- Issue
- 3
- Pages
- 347-357
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2068868975
- Cited by
- 159
- References
- 4
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.